论文部分内容阅读
目的:探讨立普妥和国产阿托伐他汀对急性冠脉综合征(ACS)患者血浆炎症因子的影响。方法:将70例ACS患者随机均分为立普妥组和国产阿托伐他汀组。立普妥组于常规治疗基础上加服立普妥20mg.d-1,连用18周。国产阿托伐他汀组于常规治疗基础上加服国产阿托伐他汀20mg.d-1,连用18周。两组均于治疗前和治疗后测定血浆C反应蛋白(CRP)和白细胞介素IL-6浓度。结果:两组患者治疗18周后,患者血浆CRP和IL-6水平均较治疗前明显下降(立普妥组P=<0.01;国产阿托伐他汀组P=<0.05)。且治疗后患者血浆CRP和IL-6水平,立普妥组与国产阿托伐他汀组相比下降更为明显(P=<0.05)。结论:立普妥和国产阿托伐他汀对ACS患者都具有抗炎作用,能改善血管内斑块的炎症反应,稳定斑块,而立普妥的抗炎效果更佳。
Objective: To investigate the effects of Lipitor and domestic atorvastatin on plasma inflammatory factors in patients with acute coronary syndrome (ACS). Methods: Seventy ACS patients were randomly divided into Lipitor group and domestic Atorvastatin group. Lipitor group in the conventional treatment plus service Lipitor 20mg.d-1, once every 18 weeks. Domestic atorvastatin group on the basis of conventional treatment plus take domestic atorvastatin 20mg.d-1, once every 18 weeks. Plasma C-reactive protein (CRP) and interleukin-6 (IL-6) levels were measured in both groups before and after treatment. Results: The plasma levels of CRP and IL-6 in both groups were significantly decreased after 18 weeks of treatment (P = <0.01 in the Lipitor group, P = <0.05 in the atorvastatin group). After treatment, the level of CRP and IL-6 in plasma was significantly lower in the Lipitor group than in the Atorvastatin group (P = <0.05). CONCLUSION: Lipitor and domestic atorvastatin have anti-inflammatory effects on patients with ACS, which can improve the inflammatory reaction and plaque of intravascular plaque, while the anti-inflammatory effect of Lipitor is better.